Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bank of America Corp (BAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bank of America Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Bank of America Corp trades at $59.81 (market cap $423.45B). The key difference: Bank of America Corp is far larger — about 10.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Bank of America Corp pays a 1.88% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BAC | |
|---|---|---|
Market Cap | $39.89B | $423.45B |
Sector | Health | Financials |
52-Week High | $491.22 | $59.90 |
52-Week Low | $278.09 | $44.92 |
Enterprise Value | $38.15B | — |
Volume | — | 55,637,172 |
Dividend Yield | — | 1.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Bank of America (BAC) trades at $59.67, up 0.71% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats and revenue growth to $113.1B in 2025 highlight fundamental strength. The stock is supported by a $2T+ deposit base and positive sentiment from media coverage of its strategic initiatives, including partnerships and hiring.
Outlook remains positive with a $63.79 consensus price target, though risks include volatile cash flows and regulatory scrutiny. Investment appeal lies in earnings momentum and potential capital returns post-stress tests, balanced by macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →
